Rafferty Asset Management, LLC Myovant Sciences Ltd. Transaction History

Rafferty Asset Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$24.03 - $27.02 $2.75 Million - $3.09 Million	114,534 Added 70.59%	276,787 $7.46 Million
Q3 2022 Nov 14, 2022	BUY	$11.6 - $20.44 $659,831 - $1.16 Million	56,882 Added 53.98%	162,253 $2.91 Million
Q2 2022 Aug 12, 2022	SELL	$7.78 - $14.69 $1.29 Million - $2.43 Million	-165,686 Reduced 61.13%	105,371 $1.31 Million
Q1 2022 May 13, 2022	BUY	$11.38 - $16.4 $214,706 - $309,418	18,867 Added 7.48%	271,057 $3.61 Million
Q4 2021 Feb 10, 2022	BUY	$14.31 - $23.87 $1.98 Million - $3.3 Million	138,428 Added 121.68%	252,190 $3.93 Million
Q3 2021 Nov 10, 2021	SELL	$18.94 - $26.99 $31,383 - $44,722	-1,657 Reduced 1.44%	113,762 $2.55 Million
Q2 2021 Aug 10, 2021	BUY	$17.07 - $24.56 $1.97 Million - $2.83 Million	115,419 New	115,419 $2.63 Million

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Rafferty Asset Management, LLC with notifications on news.